Oxford Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Oxford Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-431	Closed	-$47K	–	2077
2018 Q4	$47K	Buy	+431	New	+$86.2K	﹤0.01%	1706
2018 Q3	–	Sell	-211	Closed	-$461K	–	1987
2018 Q2	$461K	Buy	+211	New	+$535K	0.01%	1370

Other funds holding ONCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxford Asset Management's ONCT Position: Q1 2019 in Review

Oxford Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 431 shares — an estimated $47K sold.

Oxford Asset Management first reported a position in ONCT in Q2 2018 and held it in 2 quarters. The position peaked at $461K in Q2 2018. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

Oxford Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 431 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $47K.
Oxford Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
Oxford Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $461K in Q2 2018.
35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.